Article
Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers.
Cancer letters - 1 Jul 2017
Sokolenko Anna P, Savonevich Elena L, Ivantsov Alexandr O, Raskin Grigory A, Kuligina Ekatherina S, Gorodnova Tatiana V, Preobrazhenskaya Elena V, Kleshchov Maxim A, Tiurin Vladislav I, Mukhina Marina S, Kotiv Khristina B, Shulga Andrey V, Kuznetsov Sergey G, Berlev Igor V, Imyanitov Evgeny N
Abstract excerpt
Ovarian carcinomas (OC) often demonstrate rapid tumor shrinkage upon neoadjuvant chemotherapy (NACT). However, complete pathologic responses are very rare and the mechanisms underlying the emergence of residual tumor disease remain elusive. We hypothesized that the change of somatic BRCA1 status may contribute to this process. The loss-of-heterozygosity (LOH) at the BRCA1 locus was determined for 23 paired tumor...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.